Leap Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDLeap Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings contraction of 24% provides fundamental context to the price action. Investors should exercise caution due to high volatility (190% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.64 | +20.27% | ABOVE |
| 50 SMA | $0.76 | +1.66% | ABOVE |
| 100 SMA | $1.01 | -23.89% | BELOW |
| 150 SMA | $0.81 | -4.79% | BELOW |
| 200 SMA | $0.69 | +11.25% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LPTX in an uptrend right now?
LPTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is LPTX overbought or oversold?
LPTX's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.
Is LPTX outperforming the market?
LPTX has a Relative Strength (RS) Rating of 82 out of 99. Yes, LPTX is a market leader, outperforming 82% of all stocks over the past 12 months.
Where is LPTX in its 52-week range?
LPTX is trading at $0.77, which is 21% of its 52-week high ($3.70) and 15% above its 52-week low ($0.23).
How volatile is LPTX?
LPTX has a Beta of 2.71 and 52-week volatility of 190%. It's more volatile than the S&P 500 - expect bigger swings.